Trials / Sponsors / Anthos Therapeutics, Inc.
Anthos Therapeutics, Inc.
Industry · 6 registered clinical trials — 1 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Hav Atrial Fibrillation (AF) | Phase 3 | 2022-12-27 |
| Terminated | A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Assoc Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism | Phase 3 | 2022-09-27 |
| Terminated | Study in Atrial Fibrillation (AF) Patients at High Risk of Stroke Atrial Fibrillation | — | 2022-09-14 |
| Terminated | A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism | Phase 3 | 2022-05-05 |
| Active Not Recruiting | Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation Atrial Fibrillation (AF), Stroke | Phase 2 | 2021-02-02 |
| Completed | A Dose-range Finding Study of MAA868 in Patients With Atrial Fibrillation Atrial Fibrillation | Phase 2 | 2019-12-11 |